The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
|Brand Name||Generic Name||Therapeutic Area||Recommendation Type||Project Status||Date Submission Received||Date Recommendation Issued Sort descending|
|Lynparza||Olaparib||CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer||Not filed|
|Tafinlar and Mekinist||Dabrafenib and Trametinib||NSCLC BRAF V600||Complete|
|Ledaga||chlormethine hydrochloride||T-cell lymphoma||Active|
|Tysabri||natalizumab||Multiple Sclerosis, relapsing-remitting||Suspended|